MoonLake Immunotherapeutics

MoonLake Immunotherapeutics insiders are currently net buyers of MLTX stock, showing neutral sentiment over the past 90 days. Executives have purchased $126.2M while selling $90.6M, resulting in a positive net flow of $35.7M. This buying activity represents 58% of total transaction volume.

MoonLake Immunotherapeutics has 15 active insiders who have filed SEC Form 4 transactions in the past 90 days. Bihua Chen (Executive) leads with 34 transactions totaling $105.8M. Global Healthcare Master Fund, Lp Cormorant (Executive) follows with 5 transactions worth $46.9M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. MoonLake Immunotherapeutics's current score of 58/100 indicates neutral insider sentiment. Scores between 40-60 represent neutral or mixed activity. With $126.2M in purchases and $90.6M in sales, no strong directional conviction is evident.

The most recent insider transaction occurred on Jul 20, 2026, when Reich Kristian (Chief Scientific Officer) disposed of 43,700 shares at $20.09 per share for $877.9K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, MLTX insider trading sentiment is currently neutral with an Alignment Score of 58/100. The balanced activity—$126.2M bought vs $90.6M sold—suggests no strong consensus among insiders.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like MoonLake Immunotherapeutics. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At MLTX, we track all Form 4 filings—currently showing 124 transactions from 15 insiders over 90 days.

A 10b5-1 plan allows MoonLake Immunotherapeutics executives to pre-schedule stock sales when they don't possess material non-public information. At MLTX, approximately 16% of recent transactions are 10b5-1 trades. The remaining 84% are discretionary trades, which may carry more informational value.

You can monitor MoonLake Immunotherapeutics (MLTX) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 15 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. MoonLake Immunotherapeutics's current score of 58/100 indicates neutral sentiment with balanced buying and selling activity. This is calculated from $126.2M in purchases versus $90.6M in sales over 90 days, resulting in a net flow of $35.7M.

SEC Form 4 filings are mandatory reports that MoonLake Immunotherapeutics insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At MLTX, the most common type is "S" with 29 occurrences. The most recent Form 4 was filed on Jul 20, 2026 by Reich Kristian.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At MoonLake Immunotherapeutics, approximately 16% of recent transactions are executed under 10b5-1 plans, while 84% appear to be discretionary trades. The low percentage means most insider activity at MLTX represents discretionary decisions with more informational value.